10-Q: BioSig Technologies Reports Q3 2024 Results Amidst Restructuring and Nasdaq Reinstatement

BioSig Technologies reports its Q3 2024 results, highlighting a significant reduction in operating expenses, a gain from debt settlement, and the reinstatement of its Nasdaq listing, while also noting ongoing financial challenges and internal control weaknesses.

Summary

• BioSig Technologies reported its financial results for the third quarter of 2024, showing minimal revenue of $27,000 for the nine-month period.
• The company experienced a net loss of $9.24 million for the nine months ended September 30, 2024, compared to a net loss of $22.56 million for the same period in 2023.
• Operating expenses decreased significantly, with research and development expenses dropping to $736,000 from $3.9 million year-over-year, and general and administrative expenses decreasing to $10.56 million from $18.17 million.
• The company recorded a gain of $2.4 million from the settlement and forgiveness of accounts payable.
• BioSig Technologies successfully regained compliance with Nasdaq listing requirements and its stock commenced trading on the Nasdaq Capital Market on October 23, 2024, after a period of trading on the OTCQB.
• The company completed a workforce reduction in early 2024, which significantly reduced operations in the short term.
• The company issued 2,140,744 shares of common stock for services and 2,322,747 shares for vested restricted stock units during the nine months ended September 30, 2024.
• The company has a working capital deficit of $0.9 million and cash of $0.6 million as of September 30, 2024, raising concerns about its ability to continue as a going concern.
• The company is exploring strategic partnerships and additional financing options to fund future operations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positives such as reduced operating expenses and the Nasdaq reinstatement, the significant net loss, minimal revenue, and going concern issues weigh heavily on the overall sentiment. The internal control weaknesses and ongoing litigation add to the negative outlook.

Positives

• Operating expenses have been significantly reduced, with research and development expenses decreasing by 81.21% and general and administrative expenses decreasing by 41.88% year-over-year.
• The company achieved a $2.4 million gain from the settlement and forgiveness of accounts payable.
• BioSig Technologies successfully regained its Nasdaq listing, which may improve investor confidence and access to capital.
• The company has taken steps to reduce its annual cash burn through workforce reductions.
• The company is actively seeking strategic partnerships and additional financing to support its operations.

Negatives

• The company has generated minimal revenue, with only $27,000 reported for the nine months ended September 30, 2024.
• BioSig Technologies has a working capital deficit of $0.9 million and cash of $0.6 million, raising substantial doubt about its ability to continue as a going concern.
• The company experienced a net loss of $9.24 million for the nine months ended September 30, 2024.
• The company has identified material weaknesses in its internal control over financial reporting.
• The workforce reduction has significantly reduced operations in the short term.

Risks

• The company's ability to continue as a going concern is uncertain due to its net losses and negative cash flows from operations.
• The company's reliance on external financing makes it vulnerable to market conditions and investor sentiment.
• The company's commercialization efforts may be delayed due to the workforce reduction.
• The company's internal control weaknesses could lead to inaccurate financial reporting and potential regulatory issues.
• The company faces risks related to the ongoing COVID-19 pandemic and geopolitical tensions, which could affect its ability to access capital.

Future Outlook

The company plans to continue commercializing the PURE EP System, explore strategic partnerships, and raise capital through the sale of additional equity securities or debt. They also intend to hire a team to execute a business development strategy and develop new products in the field of Pulse Field Ablation.

Management Comments

• Management believes that cost-saving measures combined with expectations of positive trends in commercial activity create the potential for the company to achieve a lower cash flow breakeven rate.
• Management is focused on the continued commercialization of the PURE EP System and other applications of the core technology.
• Management is exploring strategic partnerships and additional financing options to fund future operations.

Industry Context

The company operates in the medical device industry, specifically in the electrophysiology market. The company's technology aims to improve the standard of care in cardiac arrhythmia treatment. The company's focus on signal processing and AI-based diagnostics aligns with broader industry trends towards advanced medical technologies.

Comparison to Industry Standards

• The company's revenue is significantly lower than established medical device companies, reflecting its early commercialization stage.
• The company's operating expenses are high relative to its revenue, which is typical for companies in the research and development phase.
• The company's focus on advanced signal processing and AI aligns with industry trends, but its financial performance lags behind more established competitors.
• Comparable companies in the medical device space include Boston Scientific, Medtronic, and Abbott, which have significantly higher revenue and market capitalization.
• The company's reliance on external financing is common for early-stage medical device companies, but its current financial position is weaker than many of its peers.

Management Changes

Legal Proceedings

• The company received a threat of litigation for the termination of employment, alleging retaliation for bringing wrongful practices to the attention of the board, seeking $775,782 in compensation.
• The company received a threat of litigation seeking restitution for losses resulting from unlawful actions taken by the board, with the claimant contending losses of $1,440,000.
• A lawsuit was filed against the company, its former CEO, and former CFO, alleging failure to issue stock certificates under a restricted stock award agreement, with the plaintiff seeking at least $288,000 in damages.

Related Party Transactions

• The company issued a promissory note for $500,000 to a significant shareholder/investor.
• The company issued 500,000 shares of common stock to Frederick D Hrkac, director, for consulting services.
• The company issued 500,000 shares of common stock to Anthony Amato, CEO and director, for services.
• The company issued 50,000 shares of common stock to Anthony Amato, CEO and director, for services.
• Ferdinand Groenewald was appointed as interim CFO and is compensated at a fixed rate of $15,000 per month.

Stakeholder Impact

• Shareholders have experienced significant dilution due to the issuance of new shares.
• Employees have been impacted by the workforce reduction.
• Customers may experience delays or disruptions due to the company's restructuring.
• Suppliers may be affected by the company's financial challenges.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• The company plans to continue commercializing the PURE EP System.
• The company will explore strategic partnerships and additional financing options.
• The company intends to hire a team to execute a business development strategy and develop new products.
• The company will work to remediate the identified material weaknesses in its internal control over financial reporting.
• The company will continue to pursue the acquisition of Neuro-Kinesis Corporation.

Key Dates

Keywords

BioSig Technologies, PURE EP System, electrophysiology, medical device, Nasdaq, financial results, workforce reduction, operating expenses, capital raise, internal control, going concern